The extended life of non-small-cell lung cancer (NSCLC) patients has been achieved today by the introduction of molecular therapy in those who are positive for EGFR mutations because they receive TKI inhibitors [7]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.